Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SHR-1210”

99 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 99 results

Large-scale testing (Phase 3)Study completedNCT03134872
What this trial is testing

SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+6 more
Jiangsu HengRui Medicine Co., Ltd. 419
Testing effectiveness (Phase 2)Study completedNCT04930315
What this trial is testing

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Zhejiang University 78
Early research (Phase 1)Study completedNCT02492789
What this trial is testing

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Who this might be right for
Solid Tumors and Hematologic Malignancy
Atridia Pty Ltd. 49
Testing effectiveness (Phase 2)UnknownNCT03171220
What this trial is testing

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Who this might be right for
Advanced Malignant Solid Tumor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 40
Not applicableUnknownNCT03671265
What this trial is testing

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Who this might be right for
Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)UnknownNCT02942329
What this trial is testing

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Who this might be right for
Gastric CancerHepatocellular Carcinoma
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04295317
What this trial is testing

PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery

Who this might be right for
Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital 65
Testing effectiveness (Phase 2)Looking for participantsNCT04331093
What this trial is testing

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Who this might be right for
Acral Melanoma
Di Wu 40
Testing effectiveness (Phase 2)UnknownNCT03250962
What this trial is testing

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Chinese PLA General Hospital 280
Testing effectiveness (Phase 2)Study completedNCT04680988
What this trial is testing

SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd. 194
Testing effectiveness (Phase 2)Ended earlyNCT04294784
What this trial is testing

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Who this might be right for
Gastric CancerGastroEsophageal Cancer
Huazhong University of Science and Technology 58
Not applicableWithdrawnNCT04420130
What this trial is testing

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Who this might be right for
Pancreatic CancerLiver Metastasis
Yanqiao Zhang
Testing effectiveness (Phase 2)UnknownNCT04014101
What this trial is testing

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)UnknownNCT03912857
What this trial is testing

Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sun Yat-sen University 50
Large-scale testing (Phase 3)UnknownNCT05049681
What this trial is testing

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Who this might be right for
Esophageal Cancer
Feng Wang 234
Testing effectiveness (Phase 2)Study completedNCT02989922
What this trial is testing

Evaluate SHR-1210 in Subjects With Advanced HCC

Who this might be right for
Hepatocellular Carcinoma Non-Resectable
Jiangsu HengRui Medicine Co., Ltd. 220
Testing effectiveness (Phase 2)UnknownNCT04213898
What this trial is testing

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Henan Cancer Hospital 39
Testing effectiveness (Phase 2)UnknownNCT03085069
What this trial is testing

Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms Nec+4 more
Jiangsu HengRui Medicine Co., Ltd. 146
Large-scale testing (Phase 3)UnknownNCT03668496
What this trial is testing

SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Who this might be right for
Lung Cancer Squamous CellLung Cancer Stage IVPD-1 Antibody+1 more
Jiangsu HengRui Medicine Co., Ltd. 390
Testing effectiveness (Phase 2)Looking for participantsNCT04070040
What this trial is testing

Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Who this might be right for
Primary Central Nervous System Lymphoma
Beijing Sanbo Brain Hospital 21
Next Page